Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Mar 27, 2025
CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
Read more at globenewswire.com
